NOVO NORDISK A S annual report, Q4 FY2021

Открыть документ

Novo Nordisk A/S Form 20-F Summary

Business context and reporting period

Novo Nordisk A/S filed its annual report on Form 20-F for the fiscal year ended December 31, 2021. The filing is prepared under IFRS as issued by the IASB and reports in Danish kroner (DKK). The company is a global pharmaceutical manufacturer focused primarily on Diabetes and Obesity care, with a second Biopharm segment. Its shares trade on Nasdaq Copenhagen and its ADRs trade on the NYSE under “NVO.”

The filing is annual rather than a standalone fourth-quarter report. Several financial statement details are incorporated by reference from the 2021 Annual Report, which was not included in the provided filing text.

Financial metrics, liquidity and capital allocation

  • The filing text does not provide clear consolidated values for 2021 revenue, operating profit, net profit, earnings per share, operating margin, cash flow from operations, free cash flow, cash balances or total debt. These figures are incorporated by reference from the Annual Report 2021.
  • Obesity care sales, consisting of Saxenda and Wegovy, were DKK 8,400 million in 2021 versus DKK 5,608 million in 2020.
  • Ozempic sales were DKK 33.7 billion in 2021. Ozempic achieved a 44% U.S. new-to-brand prescription market share as of December 31, 2021.
  • Victoza sales were DKK 15,054 million in 2021 versus DKK 18,747 million in 2020.
  • U.S. sales rebate provisions were DKK 50,822 million at December 31, 2021. The amount includes provisions relating to Medicare, Medicaid, pharmacy benefit managers, managed-care plans and the 340B program.
  • Novo Nordisk stated that its financial resources were sufficient to meet requirements for at least the next 12 months. Management also stated that capital expenditure and other obligations were covered by financial resources and expected operating cash flow.
  • The company repurchased 32,345,725 B shares under the 2021 program at an average price of DKK 569.54 per share. A DKK 20 billion 2021 repurchase program was completed in February 2022, and a new DKK 22 billion program was announced for the following 12 months.
  • Planned investments included approximately DKK 16.5 billion for new and expanded Kalundborg facilities, with the facilities expected to be operational in the first quarter of 2027. Realized spending was approximately DKK 740 million at December 31, 2021.

Material changes versus the prior comparable period

  • Obesity care sales increased by approximately DKK 2.8 billion from 2020 to 2021, although the majority of sales came from Saxenda.
  • Victoza sales declined by approximately DKK 3.7 billion year over year, reflecting pressure on the mature product.
  • Wegovy was approved and launched in the United States in June 2021. Demand substantially exceeded supply, and manufacturing constraints at a contract manufacturer caused supply disruptions during the second half of 2021.
  • Novo Nordisk completed the acquisition of Dicerna Pharmaceuticals on December 28, 2021, for approximately USD 3.3 billion, or DKK 22,034 million. Preliminary identified intangible assets were DKK 18,711 million, primarily relating to RNAi technology, pipeline assets and licensing arrangements.
  • China introduced an insulin Volume Based Procurement tender in November 2021. Novo Nordisk expects reduced prices and volumes to have an estimated negative impact of approximately 3% on global sales in 2022.
  • Average U.S. realized prices declined in 2021, particularly in basal insulin, due to higher rebates and competitive pressure. A new 340B policy provided a 2021 benefit of less than 3% of U.S. net sales.
  • Deloitte replaced PricewaterhouseCoopers as statutory auditor for fiscal year 2021 as a result of mandatory auditor rotation. The prior auditor reported no disagreements or reportable events.

Guidance, outlook, risks and unusual items

  • For 2022, management expects further declines in average realized prices after rebates, predominantly in insulin, while market access is expected to remain broadly similar to 2021.
  • Wegovy supply constraints were expected to continue in the United States through the first half of 2022. The company did not expect to meet demand or allow many new patients to initiate treatment during that period, with improved supply expected in the second half of 2022. A limited launch outside the United States was expected in the second half of 2022.
  • Key risks include pricing and reimbursement pressure, competition from biosimilar and interchangeable insulin products, patent expirations, regulatory approval and clinical-development risk, manufacturing and supply-chain interruptions, product liability and legal proceedings, foreign-exchange volatility, cybersecurity and data-privacy breaches, and epidemics or pandemics.
  • The filing identifies U.S. sales rebates as a critical audit matter because provisions involve significant uncertainty regarding payer contracts, claims timing, channel mix, inventory levels and applicable laws and regulations.
  • The preliminary valuation of Dicerna’s acquired intangible assets was also a critical audit matter because it depended on forecasts of future cash flows and discount-rate assumptions.
  • Management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2021. Dicerna was excluded from management’s assessment because it was acquired only three days before year-end; its assets represented approximately 1.2% of consolidated assets and its net profit approximately 0.0% of consolidated net profit.
  • Gross revenue from Iran-related transactions with government-owned or controlled entities was not more than 1% of 2021 Group sales, and estimated related net profit was de minimis.

Important facts for investors to verify

  • Obtain the incorporated Annual Report 2021 pages 50–80 to verify consolidated revenue, profit, margins, cash flow, cash, debt, liquidity and segment results.
  • Assess the assumptions supporting the DKK 50.8 billion U.S. sales rebate provision and the effect of future 340B, Medicare, Medicaid and commercial payer developments.
  • Monitor Wegovy manufacturing capacity, demand, launch timing outside the United States and the effect of supply constraints on 2022 growth.
  • Evaluate the impact of China’s insulin Volume Based Procurement program, including the expected approximately 3% global-sales impact in 2022.
  • Review Dicerna’s purchase-price allocation, intangible-asset valuation assumptions and subsequent pipeline progress.
  • Review upcoming patent expirations, particularly for Victoza and obesity-care products, and the timing and commercial impact of generic, biosimilar and interchangeable competitors.
  • Verify the funding, timing and execution risks associated with the planned multibillion-DKK manufacturing investments and share-repurchase programs.